Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).

@article{Joly2002EfficacyOZ,
  title={Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).},
  author={V. L. Joseph Joly and Philippe Flandre and Vincent Meiffr{\'e}dy and Françoise Brun-V{\'e}zinet and J. Gastaut and C{\'e}cile Goujard and G{\'e}rard R{\'e}my and Diane Descamps and Annick Ruffault and Agn{\`e}s Certain and J P Aboulker and Patrick G Yeni},
  journal={Antimicrobial agents and chemotherapy},
  year={2002},
  volume={46 6},
  pages={1906-13}
}
We compared the efficacy and the toxicity of zidovudine (AZT) versus stavudine (d4T), in combination with lamivudine (3TC) and indinavir, in AZT-, dideoxyinosine (ddI)-, and/or dideoxycytosine (ddC)-experienced patients in a randomized comparative multicenter trial. One hundred seventy human immunodeficiency virus type 1 (HIV-1)-infected patients, who had received AZT, ddI, and/or ddC for at least 6 months but were naive for d4T, 3TC, and protease inhibitors, were randomized to AZT at 250 to… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-6 of 6 extracted citations

Similar Papers

Loading similar papers…